EU/3/09/684

Table of contents

About

On 28 October 2009, orphan designation (EU/3/09/684) was granted by the European Commission to AB Science, France, for masitinib mesylate for the treatment of pancreatic cancer.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 2 September 2009 recommending the granting of this designation.

Key facts

Active substance
Masitinib mesilate
Disease / condition
Treatment of pancreatic cancer
Date of decision
27/10/2009
Outcome
Positive
Orphan decision number
EU/3/09/684

Sponsor's contact details

AB Science
3, avenue George V
75008 Paris
France
Tel. +33 1472 02311
Fax +33 1472 02411
E-mail: contact@ab-science.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating